Search results
Results From The WOW.Com Content Network
To be eligible for the MammaPrint gene expression profile, a breast cancer should have the following characteristics: stage 1 or 2, tumor size less than 5.0 cm, estrogen receptor positive (ER+) or estrogen receptor negative (ER-).
Triple-negative breast cancer comprises 15–20% of all breast cancer cases [3] and affects more young women or women with a mutation in the BRCA1 gene than other breast cancers. [4] Triple-negative breast cancers comprise a very heterogeneous group of cancers. TNBC is the most challenging breast cancer type to treat. [5]
Invasive carcinoma NST is one of the most common types of all breast cancers, accounting for 55% of breast cancer incidence. [2] Of the invasive breast cancers, invasive carcinoma NST accounts for up to 75% of cases. [3] [4] It is also the most common form of breast cancer occurring in men, accounting for 85% of cases. [5] [6]
Triple-negative breast cancer (up to 15% of cases) and inflammatory breast cancer (up to 5% of cases) are particularly aggressive and have relatively poor prognoses. [ 82 ] [ 83 ] Those with triple-negative breast cancer have an overall five-year survival rate of 77% – 91% for those whose tumors are confined to the breast; 12% for those with ...
Histopathologic types of breast cancer, with relative incidences and prognoses, with "invasive lobular carcinoma" at top right. Invasive lobular carcinoma (ILC) is breast cancer arising from the lobules of the mammary glands. [ 1] It accounts for 5–10% of invasive breast cancer. [ 2][ 3] Rare cases of this carcinoma have been diagnosed in men ...
Oncology, pathology. Medullary breast carcinoma is a rare type of breast cancer [1] that is characterized as a relatively circumscribed tumor [2] with pushing, rather than infiltrating, margins. It is histologically characterized as poorly differentiated cells with abundant cytoplasm and pleomorphic high grade vesicular nuclei. [3]
In response to her diagnosis, her close friends launched the TNBC Foundation to raise awareness and support research for this particular type of breast cancer. [2] Block-Zenna died of the disease in 2007, 2 1 ⁄ 2 years after her diagnosis. [2] At the time, little was known about triple negative breast cancer, and research efforts were minimal.
MammaPrint. MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. [ 1] It gives a binary result, high-risk or low-risk classification, and helps physicians determine whether or not a patient will benefit from chemotherapy.